Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway.

Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway.

Therapeutic response to selective serotonin (5-HT) reuptake inhibitors in Major Depressive Disorder (MDD) varies considerably among patients, and the onset of antidepressant therapeutic action is delayed until after 2 to 4 weeks of treatment. The objective of this study was to analyze changes within...

Full description

Bibliographic Details
Main Authors: Hongjie Zhu, Mikhail B Bogdanov, Stephen H Boyle, Wayne Matson, Swati Sharma, Samantha Matson, Erik Churchill, Oliver Fiehn, John A Rush, Ranga R Krishnan, Eve Pickering, Marielle Delnomdedieu, Rima Kaddurah-Daouk, Pharmacometabolomics Research Network
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3714282?pdf=render

Internet

http://europepmc.org/articles/PMC3714282?pdf=render

Similar Items